Overview

Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the pharmacokinetics (PK), safety and tolerability of 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of Granisetron Hydrochloride Nasal Sprays (GNS) as compared to Granisetron IV Injection and Granisetron Tablet in healthy Volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Maxinase Life Sciences Ltd.
Collaborator:
Tri-Service General Hospital
Treatments:
Granisetron